Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

    brain
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. Insights
  3. Blog
  4. Best practices for KPI management in FSP partnerships

Best practices for KPI management in FSP partnerships

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Sponsors and CROs in a Functional Service Provider (FSP) model share the same objectives; to deliver the clinical study safely, effectively and efficiently. Whilst the ways in which partnerships track performance and achievement of these goals can vary across organisations, a constant fundamental assumption is that key performance indicators (KPIs) should be selected, designed and articulated so that resulting outcomes support the achievement of the sponsor’s overarching business strategy. Here, we share some best practices for KPI creation and management to ensure success in your program. 

Selecting the right KPIs

In our experience, the KPIs which are most successful in driving the “right performance” are those that align both with KPIs measured internally by the Sponsor and the partnership’s objectives. This is especially true at the beginning of an FSP partnership. Orienting the teams around meaningful, shared KPIs facilitates an ease of understanding, ensures buy-in and fosters deeper collaboration across the organisations while allowing for discovery of partnership insights.

In terms of the number of KPIs, we have found that articulating and overseeing multiple performance measures does not aid transparency and can be a drain on much needed resources. We suggest sticking to those measures that directly contribute to the desired objectives, and often between six and ten measures are likely to be key for most partnerships.

In the early stages of the model, KPIs may be more tactical and focused on measures designed to understand certain logistical aspects, for example Assurance of Supply (recruitment), Operational Excellence and Delivery. Whilst we suggest committing to tracking and managing the same KPIs for about a year to create consistency in data and reporting, it is important to continuously reflect on whether those KPIs remain relevant over time. Strategies and objectives are dynamic and will change, making it inappropriate to continue to report on the same KPIs indefinitely. Equally, more data may become available that provides a deeper understanding of the workings of the program and this should result in different or additional KPIs becoming applicable.

 

Successfully measuring KPIs

Once the number and type of indicators are agreed, it is important to ensure they can be measured to determine successful performance and progress (or regression) toward achieving the overall program goals. To ensure your indicators will provide robust data for performance analysis, targets should follow the SMART formula:

  • Specific: There should be one accepted definition of the KPI, and it should be highly visible to the relevant stakeholders.
  • Measurable: The KPI should be easily quantifiable to state the actual performance versus target performance, e.g., voluntary turnover.
  • Achievable: The target should be challenging but achievable. Sought after performance standards should be realistic, even if challenging.
  • Relevant: Is the measure practical and pragmatic? A KPI provides more insight into performance if it is consistent with the current program context and can only be only relevant if our processes and people can influence it.
  • Time framed: Values of KPIs should be expressed in a specified time frame. We suggest targets be relatively short-term measurements to ensure the appropriate tracking of program performance over the longer term.

 

Ensuring data quality for KPIs

Data quality is inherently tied to performance measurement. KPIs are only as good as the reliability of the data associated with them, and so a data strategy covering the following elements should be well defined from the outset:

Data source: Where does the data originate? Be as specific as possible in identifying sources, including mentioning specific directories or file names if necessary.

Data extraction moment: At which point in time is the data is fed into the KPI? Note the exact extraction moment as closely as possible, for example at noon CET or the first day of every week.

Data update frequency: How often is the data refreshed per period? Determine if the data is real-time, weekly or bi-weekly, etc.

Data supplier: Which individual or department is responsible for delivering the source data?

KPI owner: Which individual is ultimately responsible for KPI availability and accuracy? A named owner encourages accountability and responsibility.

 

Data reporting and visualisations

Data reporting is critical as it is the first step toward decision-making and acting on this information in a way that improves performance and drives better outcomes. A clear strategy should include how often and to whom data will be reported and should account for the different reporting needs of each measure and responsible team.

Below is a graphical representation of how data can flow within a program governance structure: 

Key performance indicator alignment meeting
Figure 1: KPI data flow within program governance structure

Data visualisations can also give life to goals and make progress tangible for teams. Some of our partners have availed of the services of our ICON Data Analytics team to create a dynamic, balanced scorecard. While no measurement is perfect or complete, creating meaningful visual data comparisons enables deeper interpretation and better decisions by teams. In addition, visualising performance over time enables us to identify trends which provides useful context in assessing underlying progress/successes. 

Functional service provider performance metrics
Figure 2: Balanced scorecard and examples of KPIs

 

Responsive KPIs for dynamic partnerships

These best practices for KPI management will help guide robust partnership controls to improve efficiencies. If planned, managed and expressed well, KPIs tell us how well the program is operating across different areas and can inform timely decision-making processes to direct appropriate actions. In so doing, we drive partnership growth and ensure performance alignment with our sponsor’s overarching objectives. 

Authored by: Triona Price Smith

Vice President, Program Management

In this section
In this section
  • Digital Disruption
    • Clinical strategies to optimise SaMD for treating mental health
    • Digital Disruption: Surveying the industry's evolving landscape
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
      • Using AI for site ID and selection
      • Applying AI to manage the risks and costs of postmarketing requirements
      • Integrating AI into Clinical Research: How AI is Enhancing Clinical Development
    • Clinical trial data anonymisation and data sharing
    • Clinical Trial Tokenisation
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • mHealth wearables
      • Cybersecurity
      • Digital Endpoints
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
    • The triad of trust: Navigating real-world healthcare data integration
    • Decoding AI in software as a medical device (SaMD)
    • Software as a medical device (SaMD)
      • Developing AI in SaMD
  • Patient Centricity
    • Accelerating clinical development through DHTs
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Representation and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • A guide to safety data migrations
      • Taking safety reporting to the next level with automation
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
      • Sponsor and CRO pharmacovigilance and safety alliances
      • Understanding the Periodic Benefit-Risk Evaluation Report
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
    • Using longitudinal qualitative research to capture the patient voice
    • Prioritising patient-centred research for regulatory approval
  • Regulatory Intelligence
    • Accelerating access
    • Meeting requirements for Joint Clinical Assessments
    • Navigating the regulatory landscape in the US and Japan:
    • Preparing for ICH GCP E6(R3) implementation
    • An innovative approach to rare disease clinical development
    • EU Clinical Trials Regulation
      • EMA guideline on computerised systems and electronic data in clinical trials
      • EU CTR Whitepaper
    • Using innovative tools and lean writing processes to accelerate regulatory document writing
    • Current overview of data sharing within clinical trial transparency
    • Global Agency Meetings: A collaborative approach to drug development
    • Keeping the end in mind: key considerations for creating plain language summaries
    • Navigating orphan drug development from early phase to marketing authorisation
    • Procedural and regulatory know-how for China biotechs in the EU
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Requirements & strategy considerations within clinical trial transparency
    • Spotlight on regulatory reforms in China
    • Demystifying EU CTR, MDR and IVDR
    • Transfer of marketing authorisation
    • Exploring FDA guidance for modern Data Monitoring Committees
    • Streamlining dossier preparation
  • Therapeutics insights
    • Endocrine and Metabolic Disorders
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Approaching the CAR T-cell therapy horizon
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • A mind for digital therapeutics
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
      • Key Considerations in Chronic Pain Clinical Trials
      • ICON survey report: CNS therapeutic development
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • Considerations for strengthening vaccine development
      • COVID-19 vaccine trials
      • COVID-19 vaccines: Post-authorisation safety surveillance
      • HIV
      • The value of dynamic transmission models
    • NASH
      • The voice of NASH investigators
    • Obesity
      • Addressing obesity's impact across the disease spectrum
      • Trends and challenges in obesity research and clinical trials
      • Obesity and beyond: embracing multi-indication potential during clinical development
      • Survey report: How today’s obesity developers are navigating a multi-indication landscape
    • Oncology
      • ICON survey report: Innovation in Oncology
      • De-risking clinical development of precision medicines in oncology
      • Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
      • The future of oncology biosimilars
    • Paediatrics
      • Paediatric Risk Assessment Map
    • Respiratory
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Cross-border enrollment of rare disease patients
      • Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
      • Diversity, equity and inclusion in rare disease clinical trials
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
      • The key to remarkable rare disease registries
      • Therapeutic spotlight: Precision medicine considerations in rare diseases
  • Transforming Trials
    • Accelerating biotech innovation from discovery to commercialisation
    • Demystifying the Systematic Literature Reviews
    • Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
    • From bottlenecks to breakthroughs
    • Linguistic validation of Clinical Outcomes Assessments
    • More than monitoring
    • Optimising biotech funding
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
      • Navigating the regulatory labyrinth of technology in decentralised clinical trials
    • eCOA implementation
    • Blended solutions insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • How investments in supply of CRAs is better than competing with the demand for CRAs
      • The evolution of FSP: not just for large pharma
      • Embracing a blended operating model
      • Observations in outsourcing: Survey results show a blended future
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Partnership insights
      • Exploring partnership culture and its impact on outsourcing and operational strategy
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
  • Value Based Healthcare
    • Strategies for commercialising oncology treatments for young adults
    • US payers and PROs
    • Accelerated early clinical manufacturing
    • Cardiovascular Medical Devices
    • CMS Part D Price Negotiations: Is your drug on the list?
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • Survey results: How to engage healthcare decision-makers
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
    • Integrating openness and precision for competitive advantage
  • Blog
  • Videos
  • Webinar Channel

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Webinar

Exploring partnership culture and its impact on outsourcing and operational strategy

Webpage

Strategic Solutions

Webpage

Strategic Solutions | Case studies

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence